Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b Trial of LY2584702 in Combination With Erlotinib or Everolimus in Patients With Solid Tumors

NCT01115803 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT01115803
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01115803 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b Trial of LY2584702 in Combination With Erlotinib or Everolimus in Patients With Solid Tumors
Lead sponsor
Eli Lilly and Company
Phase
Phase 1
Overall status
Terminated
Start date
March 31, 2010
Completion date
June 30, 2011
Enrollment
29 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, non-small cell lung, metastases, neoplasm, neuroendocrine tumors, renal cell carcinoma